<DOC>
	<DOCNO>NCT01973114</DOCNO>
	<brief_summary>The purpose study evaluate dose regimen , efficacy safety latanoprost treatment Menière 's disease .</brief_summary>
	<brief_title>Latanoprost Treatment Menière 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Meniere Disease</mesh_term>
	<mesh_term>Latanoprost</mesh_term>
	<criteria>At least 18 year age Definitive unilateral Menière 's disease ( AAOHNS 1995 ) Disease stage II III : PTA4 ( Pure Tone Average ) ( 0.5 , 1.0 , 2.0 3.0kHz ) 25dB 70dB Speech discrimination score silence : No good 85 % At least three vertigo attack ( last ≥ 20 minute ) last three month prior inclusion Tinnitus last three month prior inclusion Signed write informed consent Medical psychiatric condition could jeopardize would compromise subject 's ability participate trial decrease likelihood obtain satisfactory data achieve objective trial , dementia , alcohol substance abuse . Bilateral Menière 's disease Chronic otitis medium ear affected Menière 's disease Subjects fluent Swedish language Bronchial asthma Previous intratympanic injection gentamicin surgical therapy Previous intratympanic steroid therapy less six month prior inclusion Known hypersensitivity local anesthetic Pregnant woman Nursing mother</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Menière 's disease</keyword>
	<keyword>Vertigo</keyword>
	<keyword>Hearing loss</keyword>
	<keyword>Tinnitus</keyword>
</DOC>